Tessera Therapeutics is pioneering Gene Writing—a revolutionary genome engineering technology that is designed to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source

Tessera Therapeutics raised over $230 million in the Series B round from an impressive group of investors to accelerate the research and development of their technology platform